Edwards’ Resilient Trial Demonstrates Statistically Superior Results For Treating Peripheral Arterial Disease In The Leg

Edwards Lifesciences Corporation (NYSE: EW), a world leader in products and technologies to treat advanced cardiovascular disease, announced the 12-month results from The RESILIENT Trial, presented as the “Blockbuster” Trial of the Day at the Cardiovascular Research Foundation’s 19th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C. [click link for full article]

More: continued here

Filed under: Cardiovascular on October 25th, 2007